Quark Pharmaceuticals To Present Data On Its SiRNA Therapeutic Programs In Kidney And Lung Diseases

Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D.